Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-29T17:04:08.428Z Has data issue: false hasContentIssue false
  • English
  • Français

The role of serotonin in Parkinsons' Disease: An integrated approach for research of motor, cognitive and affective symptoms with functional intervention studies

Published online by Cambridge University Press:  18 September 2015

A.F.G. Leentjens ,
F.R.J. Verhey ,
F.W. Vreeling  and
H.M. van Praag
A.F.G. Leentjens*
Affiliation:
Afdeling Psychiatrie Instituut Hersenen en Gedrag, Universiteit Maastricht
F.R.J. Verhey
Affiliation:
Afdeling Psychiatrie Instituut Hersenen en Gedrag, Universiteit Maastricht
F.W. Vreeling
Affiliation:
Afdeling Neurologie Instituut Hersenen en Gedrag, Universiteit Maastricht
H.M. van Praag
Affiliation:
Afdeling Psychiatrie
*
Academisch Ziekenhuis Maastricht, A.F.G. Leentjens, Postbus 5800, 6202 AZ Maastricht
Get access Rights & Permissions [Opens in a new window]

Summary

Serotonin seems to play an important role in the regulation of dopaminergic and cholinergic neurotransmitter activities. In patients with Parkinsons' Disease, serotonergic activity is generally reduced, which is considered a compensating mechanism for the reduced dopaminergic activity. At the same time, reduction of serotonin activity may play a role in the expression of cognitive and affective symptoms. Functional intervention with serotonergic agents makes it possible to temporarily enhance or reduce the availability of serotonin in the brain. This will provide the opportunity to study motor, cognitive and affective symptoms in an integrated approach. This type of research has hardly been preformed in patients with Parkinson's Disease.

Keywords

serotonindopaminacetylcholineSleutelwoorden: serotoninedopamineacetylcholine
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 10 , Issue 4 , December 1998 , pp. 84 - 86
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1. Parkinson, J. An essay on the shaking palsy. London: Sherwood, Neely and Jones, 1817.Google Scholar
2. Möhr, E, Mendts, T, Grimes, JD. Late cognitive changes in Parkinson's Disease with an emphasis on dementia. Adv Neurol 1995; 65: 97–113.Google ScholarPubMed
3. Cummings, JL. Depression and Parkinson's Disease: A review. Am J Psychiat 1992; 149: 443–54.Google ScholarPubMed
4. Törk, I. Anatomy of the serotonergic system. In: Whitaker-Azmitia, PM, Proutka, S, eds. The Neuropharmacology of Serotonin. New York, 1990: 9–35. Ann NY Ac Sci 1990; 600.Google Scholar
5. Jacobs, BL, Fornai, CA. 5-HT and motor control: A hypothesis. Trends Neurose 1993; 16: 346–52.10.1016/0166-2236(93)90090-9CrossRefGoogle ScholarPubMed
6. Jellinger, K. An overview of morphological changes in Parkinson's disease. Adv Neurol 1986; 45: 1–18.Google Scholar
7. Birkmayer, W, Riederer, P. Biochemische Veranderungen bei der Parkinson-Krankheit. In: Birkmayer, W, Riederer, P, eds. Die Parkinson-Krankheit; Biochemie, Klinik, Therapie. Wien: Springer-Verlag, 1985: 29–59.10.1007/978-3-7091-2262-4CrossRefGoogle Scholar
8. Hornykiewicz, O. Brain neurotransmitter changes in Parkinson's Disease. In: Marsden, CD, Fahn, S, eds. Movement Disorders. London: Butterworths, 1982: 41–58.Google Scholar
9. Johanson, B, Roos, B-E. 5-Hydroxyindoleacetic and homvanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. Life Sci 1967; 6: 1449–54.10.1016/0024-3205(67)90193-2CrossRefGoogle Scholar
10. Mayeux, R, Stern, Y, Cote, L, Williams, BW. Altered serotonin metabolism in depressed patients with Parkinson's Disease. Neurol 1984; 34: 642–6.10.1212/WNL.34.5.642CrossRefGoogle ScholarPubMed
11. Hall, CD, Weiss, EA, Morris, CE, et al. Rapid deterioration in patients with parkinsonism following tryptophan-pyridoxine administration. Neurol 1972; 22: 231–7.CrossRefGoogle ScholarPubMed
12. Chase, TN, Ng, LKY, Watanabe, AM. Parkinson's disease; modification by 5-hydroxytryptophan. Neurol 1972; 22: 479–84.10.1212/WNL.22.5.479CrossRefGoogle ScholarPubMed
13. Volpi, R, Caffarra, P, Boni, S, et al. ACTH/cortisol involvement in the serotonergic disorder affecting the Parkinsonian Brain. Neuropsychobiol 1997; 35: 73–8.10.1159/000119394CrossRefGoogle ScholarPubMed
14. Kostie, VS, Lecic, D, Doder, M, et al. Prolactine and Cortisol responses to fenfluramine in Parkinson's disease. Biol Psychiat 1996; 40: 769–75.10.1016/0006-3223(95)00496-3CrossRefGoogle Scholar
15. Cassel, J-C, Jeltsch, H. Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neurose 1995; 69: 1–41.Google ScholarPubMed
16. Little, JT, Broocks, A, Martin, A, et al. Serotonergic modulation of anticholinergic effects on cognition and behaviour in elderly humans. Psychopharmacol 1995; 120: 280–8.10.1007/BF02311175CrossRefGoogle ScholarPubMed
17. Vitiello, B, Martin, A, Hill, J, et al. Cognitive and behavioural effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacol 1997; 16: 15–24.10.1016/S0893-133X(96)00134-0CrossRefGoogle ScholarPubMed
18. Riedel, W, Klaassen, T, Deutz, NEP, et al. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. Psychopharmacol (accepted).Google Scholar
19. Praag, HM van, De Haen, S. Central serotonergic metabolism and frequency of depression. Psychiat Res 1979; 1: 219–24.CrossRefGoogle Scholar
20. Mayeux, R. The ‘serotonergic hypothesis’ for depression in Parkinson's Disease. Adv Neurol 1990; 53: 163–6.Google Scholar
21. Leo, RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiat 1996; 57: 449–54.CrossRefGoogle ScholarPubMed